Chemical Structure (Levetiracetam 01)
Levetiracetam Solution
Product Images NDC 51672-4136
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 51672-4136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Levetiracetam 02)
Figure 2 (Levetiracetam 03)
This appears to be a chart or a table that compares the effectiveness of a placebo versus two doses of levotiracetam (1000 mg/day and 2000 mg/day) in an unknown study. The rows seem to represent different percentages (35.2% and 6.3%), while the columns may detail the number of patients in each group (N) and may differentiate between the different doses of levotiracetam. Without more context or information, it is difficult to provide a more detailed description.*
Figure 3 (Levetiracetam 04)
Figure 4 (Levetiracetam 05)
This is a table showing the percentage distribution of patients in a clinical trial between a placebo group (97 patients) and a treatment group taking Levetiracetam (101 patients). However, there is no information regarding what is being studied or what the percentages represent.*
Figure 5 (Levetiracetam 06)
This text seems to contain numerical data related to a comparison of placebo and levetiracetam, a medication used to treat seizures. The numbers 19.6% and 431% could represent the effectiveness of the medication in some way, but without additional context, it is impossible to interpret the meaning correctly. The text also indicates that the study had 51 participants in the placebo group and 58 participants in the levetiracetam group.*
Figure 6 (Levetiracetam 07)
Principal Display Panel (250 mg Tablet Bottle Label)
This appears to be a collection of drug-related information, including various identification numbers and dosage instructions, as well as a pharmacist's recommendation to store the medication in a tightly sealed, tamper-resistant container. The specific drug being referred to is unclear from this text, however, so further information would be needed to provide a more accurate description.*
Principal Display Panel (500 mg Tablet Bottle Label)
Principal Display Panel (750 mg Tablet Bottle Label)
This is a medication package for Levetiracetam tablets. The package contains 30 tablets of 6° strength, and the pharmacist is advised to dispense it in a light-resistant container with a child-resistant closure. The usual dosage and prescribing information can be found in the package insert. The tablets should be stored at 20°-25°C. The package also includes a medication guide for patients. The tablets are distributed by Taro Pharmaceuticals USA, based in Hawthorne, NY.*
Principal Display Panel (1000 mg Tablet Bottle Label)
This text is a prescription label for Levetiracetam medication produced by Taro Pharmaceutical Industries Limited and distributed by Taro Pharmaceuticals USA. It advises to dispense the medication in a tightly sealed container with a child-resistant closure and to store it at a temperature between 20°C-25°C. The label also indicates that the usual dosage should be determined by the package insert and full prescribing information.*
Principal Display Panel (473 mL Bottle Label)
This is a medication called Levetiracetam Oral Solution, USP designed for prescription use only. The usual dosage information is available in the package insert. The medication guide is required for each patient. It should be stored in a light-resistant and child-resistant container at a controlled room temperature of 20°-25°C (68°77°F). The medication is manufactured by Taro Pharmaceuticals Industries Ltd in Israel, and it is distributed by Taro Pharmaceuticals U.S.A., Inc. The trademark of the product is TARO.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
